Conflicts of interest M.K.S. and I.O. are employed by Astellas Pharma, which supported this study financially.
Economic evaluation of maintenance treatment with tacrolimus 0·1% ointment in adults with moderate to severe atopic dermatitis
Article first published online: 8 SEP 2008
© 2008 The Authors. Journal Compilation © 2008 British Association of Dermatologists
British Journal of Dermatology
Volume 159, Issue 6, pages 1322–1330, December 2008
How to Cite
Wollenberg, A., Sidhu, M.K., Odeyemi, I., Dorsch, B., Koehne-Volland, R., Schaff, M., Ehlken, B. and Berger, K. (2008), Economic evaluation of maintenance treatment with tacrolimus 0·1% ointment in adults with moderate to severe atopic dermatitis. British Journal of Dermatology, 159: 1322–1330. doi: 10.1111/j.1365-2133.2008.08807.x
- Issue published online: 19 NOV 2008
- Article first published online: 8 SEP 2008
- Accepted for publication 1 June 2008
- atopic dermatitis;
- cost analyses;
- health-related quality of life;
- prophylactic treatment
Background Rational health care decision-making based on outcomes and economic evidence is essential to provide the best possible care for individual patients with atopic dermatitis (AD).
Objectives To describe treatment outcomes and to evaluate resource utilization and associated cost of maintenance use of tacrolimus ointment (MU) vs. standard use of tacrolimus ointment (SU) in adults with AD.
Methods A pan-European, phase III multicentre randomized clinical trial was conducted. Patients with mild to severe AD were randomized to tacrolimus 0·1% ointment (MU) or vehicle (SU) twice per week for 12 months. Disease exacerbations were treated by using open-label tacrolimus 0·1% ointment twice daily. Resource utilization data were collected prospectively alongside the clinical trial. Costs of pooled resource data were determined using German unit cost data. Direct and indirect costs were considered from third party payer, patient and societal perspectives.
Results All patients with moderate and severe AD were included in a subanalysis, 75 patients in the MU arm (57% moderately affected) and 59 patients in the SU arm (59% moderately affected). In patients with moderate AD, the number of disease exacerbations in the MU arm was 2·4 vs. 5·5 in the SU arm (P < 0·001); in patients with severe AD corresponding figures were 2·3 vs. 7·4 (P < 0·001), respectively. Mean ± SD total annual cost per patient was €1525 ± 1081 (MU) vs. €1729 ± 1209 (SU) in patients with moderate AD and €2045 ± 2013 (MU) vs. €2904 ± 1510 (SU) in patients with severe AD.
Conclusions Maintenance treatment with 0·1% tacrolimus ointment is more effective and leads to cost savings and improved health-related quality of life in comparison with standard use of 0·1% tacrolimus ointment, especially in patients with severe AD.